Abstract 261P
Background
Ovarian germ cell tumour (GCT) is a potentially curable malignancy generally occurring in young females. The impact of various social stigmas on these women is profound especially among the lower socioeconomic classes from developing countries. The data on the epidemiology and potential challenges in management will help to fine-tune our approach.
Methods
A Retrospective analysis of ovarian GCTs treated at our institute from 2011 to 2017 was carried out. Our aim was to study the epidemiology, salient features and long-term outcomes in ovarian GCTs.
Results
There were 14 benign teratomas and 35 malignant tumours. 12 were mixed GCTs ,11 were dysgerminomas, 6 were yolk sac tumours, 5 were immature teratomas and there was 1 pure Choriocarcinoma. The median age at presentation for malignant tumours was 21.14years and for benign teratomas was 40 years. Pain was the presenting complaint in 74%, mass in 20% and 5%came with ascites. Bilaterality observed in 20%dysgerminoma,14%benign teratomas and 8%mixed tumours. Those with FIGO stage1 was 58% and 38% were stage3 at presentation. Mean size of dysgerminomas was 12cm and 14cm for non-dysgerminomas. Three cases diagnosed antenatally underwent LSCS along with definitive surgery at term and another patient underwent early MTP. Fertility sparing surgery was done in 63.4% benign and 60% of malignant cases. There was no indication for chemotherapy in 6 patients. Neoadjuvant chemotherapy was given for 4 patients and adjuvant for the rest(BEP). After chemotherapy 15%developed ovarian failure. Nausea, vomiting, diarrhoea and neutropenia were the common adverse events.6 patients defaulted after surgery. All dysgerminomas and teratomas achieved complete remission and the overall rate was 93.3%. Recurrence at 45month follow-up was 18% but zero for dysgerminoma. Most recurrences were within 2years (75%). OS during the period was 88.5%.
Conclusions
Malignant ovarian GCTs occur in younger females and benign ones more in the middle age. The long-term outcomes are generally excellent. Non-dysgerminoma histology, inadequate surgery and advanced stage are poor prognostic factors. The social stigmas associated with a diagnosis of cancer seemed to adversely impact the treatment compliance and long term follow up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The presenting author.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract